Prostate Specific Antigen (PSA), encore combien de d茅g芒ts聽?

详细信息	查看全文 | 推荐本文 |

• 作者：Alain Braillon¹ ; ^{braillon.alain@gmail.com} ; Catherine Hill² ; Gé ; rard Dubois³
• 刊名：La Presse M¨|dicale
• 出版年：2012
• 期刊代码：pca289_07554982
• 类别：med
• 出版时间：May, 2012
• 卷：41
• 期：5
• 页码：482-485
• 文件大小：102 K

摘要

| ReferencesReferencesg="UTF-8"?>

Key points

g class="boldFont">Screening for prostate cancer has been widely promotedg> since the early 1990s despite the lack of evidence of its efficacy.

g class="boldFont">The US Preventive Services Task Force recommended against PSA screeningg> because there is sufficient evidence that the harms of screening outweigh its benefits.

Yet more than g class="boldFont">half of French doctors are in favor of screeningg> and the use of PSA assays continue to grow, by 4.6%between 2009 and 2010.

The sale of a g class="boldFont">rapid immunological test for PSAg>, intended for home use, can only aggravate a situation already out of control.

g class="boldFont">The role of the French authoritiesg> in the present situation cannot be ignored.